Cipher Pharmaceuticals Inc. (TSX:CPH)

Market Cap	380.15M
Revenue (ttm)	64.91M
Net Income (ttm)	16.56M
Shares Out	25.39M
EPS (ttm)	0.64
PE Ratio	23.55
Forward PE	17.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,309
Average Volume	21,961
Open	15.11
Previous Close	14.94
Day's Range	14.69 - 15.11
52-Week Range	10.61 - 19.69
Beta	0.51
RSI	68.51
Earnings Date	Aug 7, 2025

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients; Vaniqa...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CPH

Financial Performance

In 2024, Cipher Pharmaceuticals's revenue was $33.36 million, an increase of 57.66% compared to the previous year's $21.16 million. Earnings were $11.55 million, a decrease of -43.36%.

Financial numbers in USD